Tower Research Capital LLC (Trc) Biocryst Pharmaceuticals Inc Transaction History

Tower Research Capital LLC (Trc)

$3.29 Billion
Q1 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,936 shares of BCRX stock, worth $69,845. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,936

Previous 23,083 69.95%

Holding current value

$69,845

Previous $173,000 69.94%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.06 - $9.39 $113,997 - $151,620	-16,147 Reduced 69.95%	6,936 $52,000
Q4 2024 Feb 13, 2025	BUY	$7.03 - $8.43 $74,398 - $89,214	10,583 Added 84.66%	23,083 $173,000
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $282,386 - $382,829	-44,054 Reduced 77.9%	12,500 $95,000
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $218,613 - $359,415	52,933 Added 1461.83%	56,554 $349,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $33,247 - $52,012	-6,799 Reduced 65.25%	3,621 $18,000
Q4 2023 Feb 13, 2024	BUY	$4.98 - $6.77 $29,441 - $40,024	5,912 Added 131.14%	10,420 $62,000
Q3 2023 Nov 14, 2023	SELL	$6.71 - $7.92 $127,583 - $150,590	-19,014 Reduced 80.83%	4,508 $31,000
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $81,592 - $103,279	11,723 Added 99.36%	23,522 $165,000
Q1 2023 May 09, 2023	SELL	$7.94 - $11.84 $35,150 - $52,415	-4,427 Reduced 27.28%	11,799 $98,000
Q4 2022 Feb 10, 2023	SELL	$10.5 - $14.2 $320,113 - $432,915	-30,487 Reduced 65.26%	16,226 $186,000
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $117,093 - $160,718	10,852 Added 30.26%	46,713 $589,000
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $155,283 - $351,896	19,681 Added 121.64%	35,861 $380,000
Q1 2022 May 12, 2022	SELL	$11.56 - $19.76 $99,982 - $170,904	-8,649 Reduced 34.83%	16,180 $263,000
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $157,146 - $217,305	-14,056 Reduced 36.15%	24,829 $344,000
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $275,858 - $342,639	19,413 Added 99.7%	38,885 $559,000
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $395,504 - $717,735	-41,632 Reduced 68.13%	19,472 $308,000
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $20,149 - $37,209	-2,734 Reduced 4.28%	61,104 $622,000
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $1.28 Million - $3.27 Million	-379,797 Reduced 85.61%	63,838 $475,000
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $1.18 Million - $1.9 Million	343,144 Added 341.47%	443,635 $1.52 Million
Q2 2020 Aug 13, 2020	BUY	$1.9 - $5.61 $190,932 - $563,754	100,491 New	100,491 $479,000
Q2 2019 Aug 13, 2019	SELL	$2.91 - $9.15 $1,027 - $3,229	-353 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $2,605 - $3,431	353 New	353 $3,000
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $1,322 - $1,769	-304 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$4.16 - $5.33 $38,001 - $48,689	-9,135 Reduced 96.78%	304 $1,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $38,699 - $56,350	9,439	9,439 $50,000

Others Institutions Holding BCRX

# of Institutions

292

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.87B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Biocryst Pharmaceuticals Inc Transaction History